Webster Bank N. A. Has $13.82 Million Stock Position in AbbVie Inc. $ABBV

Webster Bank N. A. lowered its position in AbbVie Inc. (NYSE:ABBV) by 4.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,925 shares of the company’s stock after selling 2,782 shares during the quarter. AbbVie makes up approximately 1.2% of Webster Bank N. A.’s holdings, making the stock its 17th biggest position. Webster Bank N. A.’s holdings in AbbVie were worth $13,821,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie in the fourth quarter valued at approximately $28,000. Imprint Wealth LLC increased its stake in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie during the 4th quarter valued at $31,000. Legacy Wealth Managment LLC ID raised its holdings in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC lifted its stake in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald upped their price objective on shares of AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Wells Fargo & Company increased their price objective on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, July 10th. Finally, Bank of America raised their price objective on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $275.50.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong post-Humira growth: AbbVie reported first-quarter 2026 revenue of $15.002 billion, up 12.4% year over year on a reported basis and 10.3% operationally. Adjusted diluted EPS of $2.65 exceeded internal expectations despite a $0.41-per-share headwind from acquired in-process research and development costs, supporting confidence in the company’s ability to replace Humira-related sales. Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?
• Positive Sentiment: Analyst support strengthened: Wolfe Research upgraded AbbVie, citing the company’s pipeline strength and valuation. BNP Paribas Exane also indicated that the stock could rise, adding to the bullish research tone. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation AbbVie Stock Price Expected to Rise, BNP Paribas Exane Analyst Says
• Positive Sentiment: Commercial and pipeline catalysts: AbbVie’s Botox filing and Canada’s reimbursement recommendation for UBRELVY in adult migraine treatment could expand revenue opportunities in aesthetics and neuroscience. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Neutral Sentiment: Updates on venetoclax in high-risk myelodysplastic syndromes and a completed Phase 3 Botox jawline study provide potential longer-term catalysts, but their financial impact depends on additional data, regulatory decisions, and commercialization. AbbVie’s Venetoclax Combo in High-Risk MDS
• Negative Sentiment: Erste Group Bank lowered its AbbVie earnings estimates, highlighting a counterpoint to the positive upgrades and potentially limiting near-term upside. Erste Group Bank Lowers Earnings Estimates for AbbVie

AbbVie Price Performance

Shares of ABBV opened at $251.20 on Friday. The company has a market capitalization of $443.82 billion, a PE ratio of 70.96, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The company’s fifty day moving average price is $244.51 and its 200 day moving average price is $225.96.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.